BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31312209)

  • 1. Use of Pharmacogenetic Drugs by the Dutch Population.
    Alshabeeb MA; Deneer VHM; Khan A; Asselbergs FW
    Front Genet; 2019; 10():567. PubMed ID: 31312209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard.
    Alshabeeb MA; Alyabsi M; Paras B
    Saudi Pharm J; 2022 Aug; 30(8):1181-1192. PubMed ID: 36164570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
    van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
    Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary Care Prescription Drug Use and Related Actionable Drug-Gene Interactions in the Danish Population.
    Lunenburg CATC; Hauser AS; Ishtiak-Ahmed K; Gasse C
    Clin Transl Sci; 2020 Jul; 13(4):798-806. PubMed ID: 32166845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population.
    Verma SS; Keat K; Li B; Hoffecker G; Risman M; ; Sangkuhl K; Whirl-Carrillo M; Dudek S; Verma A; Klein TE; Ritchie MD; Tuteja S
    J Transl Med; 2022 Nov; 20(1):550. PubMed ID: 36443877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.
    Cohn I; Manshaei R; Liston E; Okello JBA; Khan R; Curtis MR; Krupski AJ; Jobling RK; Kalbfleisch K; Paton TA; Reuter MS; Hayeems RZ; Verstegen RHJ; Goldman A; Kim RH; Ito S
    JAMA Netw Open; 2021 May; 4(5):e2110446. PubMed ID: 34037732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing Clinical Utility of Pharmacogenetic Testing in the Military Health System.
    Hellwig LD; Turner C; Olsen C; Libbus J; Markos B; Koehlmoos T; Haigney M; De Castro M; Saunders D
    Mil Med; 2024 Jan; 189(1-2):e198-e204. PubMed ID: 37436924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fetal pharmacogenomics: A promising addition to complex neonatal care.
    Raymond M; Critchlow E; Rice SM; Wodoslawsky S; Berger SI; Hegde M; Empey PE; Al-Kouatly HB
    Mol Genet Metab; 2022; 137(1-2):140-145. PubMed ID: 36029725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Cost-Consequence Analysis of Preemptive
    Brunette CA; Dong OM; Vassy JL; Danowski ME; Alexander N; Antwi AA; Christensen KD
    J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.
    Ji Y; Skierka JM; Blommel JH; Moore BE; VanCuyk DL; Bruflat JK; Peterson LM; Veldhuizen TL; Fadra N; Peterson SE; Lagerstedt SA; Train LJ; Baudhuin LM; Klee EW; Ferber MJ; Bielinski SJ; Caraballo PJ; Weinshilboum RM; Black JL
    J Mol Diagn; 2016 May; 18(3):438-445. PubMed ID: 26947514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription Patterns and Relationship to Pharmacogenomics Testing in the Military Health System.
    Selig DJ; Livezey JR; Chin GC; DeLuca JP; Guillory Ii WO; Kress AT; Oliver TO; Por ED
    Mil Med; 2021 Dec; 187(Suppl 1):9-17. PubMed ID: 34967405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of targeted vs. expanded pharmacogenomic testing: What are we missing?
    Chambal M; Forsthoffer C; Egnaczyk A; Seitz M; Grande K; Ashcraft K; Wick JA; Blaxall BC
    J Am Pharm Assoc (2003); 2023; 63(3):939-945. PubMed ID: 37024375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Use among Nursing Home Residents in Denmark for Drugs Having Pharmacogenomics Based (PGx) Dosing Guidelines: Potential for Preemptive PGx Testing.
    Vermehren C; Søgaard Nielsen R; Jørgensen S; Drastrup AM; Westergaard N
    J Pers Med; 2020 Jul; 10(3):. PubMed ID: 32752034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug-Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients.
    Westergaard N; Søgaard Nielsen R; Jørgensen S; Vermehren C
    J Pers Med; 2020 Jan; 10(1):. PubMed ID: 31963319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenes that demonstrate high association evidence according to CPIC, DPWG, and PharmGKB.
    Alshabeeb MA; Alyabsi M; Aziz MA; Abohelaika S
    Front Med (Lausanne); 2022; 9():1001876. PubMed ID: 36388934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Switzerland: A Descriptive Study Using the Helsana Database.
    Wittwer NL; Meier CR; Huber CA; Meyer Zu Schwabedissen HE; Allemann S; Schneider C
    Pharmgenomics Pers Med; 2022; 15():967-976. PubMed ID: 36447837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of preemptive pharmacogenetic testing and improvement of medication treatment satisfaction among medically underserved patients.
    Lteif C; Eddy E; Terrell J; Cavallari LH; Malaty J; Duarte JD
    Clin Transl Sci; 2024 Jan; 17(1):e13692. PubMed ID: 38013396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunities for Pharmacogenetic Testing to Guide Dosing of Medications in Youths With Medicaid.
    Tang Girdwood S; Hall M; Antoon JW; Kyler KE; Williams DJ; Shah SS; Orth LE; Goldman J; Feinstein JA; Ramsey LB
    JAMA Netw Open; 2024 Feb; 7(2):e2355707. PubMed ID: 38349656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentially actionable pharmacogenetic variants and symptom control medications in oncology.
    Patel JN; Boselli D; Jandrisevits EJ; Hamadeh IS; Salem A; Meadors P; Walsh D
    Support Care Cancer; 2021 Oct; 29(10):5927-5934. PubMed ID: 33758969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.